In vivo potentiation of cis-diamminedichloroplatinum (II) antitumor activity by pretreatment with sparsomycin
| Autor: | Harry C. J. Ottenheijm, Zbigniew Zylicz, Helga van Rennes, Willem J. de Grip, Leon A. G. M. van den Broek, Eppo van der Kleijn, J. M. C. Wessels, D. J. Theo Wagener |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
Cancer Research
Ratón Mice Inbred Strains Pharmacology chemistry.chemical_compound Mice In vivo Antineoplastic Combined Chemotherapy Protocols medicine Animals Leukemia L1210 Antitumor activity Cisplatin Cis diamminedichloroplatinum ii Antibiotics Antineoplastic Chemistry Long-term potentiation Drug Synergism Sparsomycin Oncology Immunology Female medicine.drug |
| Zdroj: | Cancer letters. 32(1) |
| ISSN: | 0304-3835 |
| Popis: | The influence of protein synthesis inhibition by sparsomycin (Sm) on in vivo cisplatin activity has been studied on BALBc X DBA2: F1 mice bearing L1210 leukemia i.p. Sm alone at the dose range from 0.5 to 3.0 mg/kg did not significantly improve animal survival. Sm potentiated cisplatin activity only when given 3 or 6 h prior to cisplatin (P less than 0.001). Sm 0.5-1.5 mg/kg 3 h prior to cisplatin resulted in a significant prolongation of animal survival (P less than 0.001) and 66% cures in each group versus 0% due to cisplatin alone. Sm pretreatment decreased weight loss due to cisplatin suggesting that it probably is able to decrease cisplatin toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|